Dupilumab in Inflammatory Skin Diseases: A Systematic Review

    March 2023 in “ Biomolecules
    Henning Olbrich, Christian D. Sadik, Ralf J. Ludwig, Diamant Thaçi, Katharina Boch
    TLDR Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
    Dupilumab, initially approved for atopic dermatitis (AD), has shown promise in treating other inflammatory skin diseases due to its mechanism of blocking interleukin (IL)-4 and -13, which are involved in type 2 inflammation. The U.S. FDA recently approved it for prurigo nodularis (PN), and its off-label use has been effective for various dermatologic conditions. A systematic review identified successful applications of dupilumab in treating bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome, and other chronic inflammatory skin diseases, highlighting its broad potential in dermatology beyond AD and PN.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    1 / 1 results

    Similar Research

    5 / 239 results